Trial Profile

To Assess Benefit risk and medical cost of direct oral anticoagulants versus low ‐ molecular ‐ weight heparins for venous thromboembolism prevention following total knee replacement. A French nationwide cohort study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Low molecular weight heparins (Primary) ; Rivaroxaban (Primary)
Indications Venous thromboembolism
Focus Therapeutic Use

24 Sep 2018 New trial record
26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com